Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

Inclusion Criteria: * male or female greater than or equal to 18 years of age * have one of the following disease states: Acute Myeloid Leukemia (AML) (age \<60 years) with relapsed/refractory disease; •Chronic Lymphocytic Leukemia (CLL) with relapsed disease following a fludarabine-based regimen or relapsed disease following an alkylator-based regimen * are recovered from the acute adverse effects of prior therapies (excluding alopecia and Grade ≤2 neuropathy). * have blast counts that can be controlled by the use of hydroxycarbamide (500 to 3000 mg daily). * have adequate hepatic function and renal function * have an estimated life expectancy of \>3 months * female subject must have a negative serum pregnancy result within 7 days before the start of the study; Both men and women must agree to use a medically acceptable form of contraception throughout the treatment period and for 3 months after discontinuation of treatment Exclusion Criteria: * are eligible for any standard therapy known to be life prolonging or life saving * have diagnosis of AML French-American-British (FAB) classification (FAB) M3 (acute promyelocytic leukemia (APL)) * are receiving concurrent chemotherapy, radiotherapy, immunotherapy, biological or hormonal treatment for cancer. * have undergone anticancer therapy including chemotherapy (except for hydroxycarbamide at a maximum daily dose of 3000 mg), endocrine therapy, immunotherapy, or the use of other investigational agents within 4 weeks before study entry. * prior radiation therapy with volume of bone marrow treated over 25%. * use of immunosuppressive therapy, including systemic steroids within 7 days before the first dose of SG2000. * hyperleukocytosis (blast counts \>30 000/mm3). * history of allogeneic stem cell or solid organ transplantation. * positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C or have HIV-AIDS, or active hepatitis B or C. * history of other invasive malignancy within 3 years except for cervical carcinoma in situ, nonmelanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has been surgically cured. * have any coexisting medical condition that will substantially increase the risk associated with the subject's participation in the study. * have psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of necessary studies. * have persistent Grade 2 or greater toxicities from any cause (except alopecia or peripheral neuropathy). * are pregnant or breast-feeding.